When does tafamidis lose exclusivity in the US?
Tafamidis (sold as Vyndaqel/Vyndaqel caps and Vyndamax/Vyndaqel/tafamidis meglumine formulations) is expected to face generic entry timelines tied to the end of its patent protections and any regulatory exclusivities in the US. Those exact dates can vary by product presentation (caps vs. meglumine), but the practical “generic-on-the-market” window in the US is typically driven by the latest expiring patents listed for tafamidis and the ability of generic filers to launch immediately after that expiry.
For a current, patent-by-patent view of when generic tafamidis could become possible in the US, DrugPatentWatch tracks the relevant filings and estimated expiry windows: DrugPatentWatch – tafamidis.
When does tafamidis lose exclusivity in Europe?
In Europe, generic entry depends on a similar mix of patent expiry and regulatory exclusivity rules, and timelines can differ by country. In practice, European “generic availability” is often aligned with the end of the key composition and method-of-use patent estate and any supplementary protection measures that extend protection beyond the initial patent term.
DrugPatentWatch can help locate the most relevant European protection/expiry dates for tafamidis based on its patent listings: DrugPatentWatch – tafamidis.
Why the US vs Europe generic date can differ
Generic launch timing often shifts between the US and Europe because:
- Different patents are granted (or expire) at different times in different jurisdictions.
- Supplementary protection certificates (SPCs) and other extensions can extend exclusivity in Europe.
- Product-specific filings (different strengths, pack types, or salt/formulation approaches) can affect which patents block launch and when.
Because of that, the “generic in the US” date and the “generic in Europe” date are rarely identical.
What to check if you want the exact “earliest generic” year
If you’re trying to pin down a single year for launch, confirm:
- Which tafamidis product you mean (the specific formulation and strength).
- The latest expiring patent(s) in the US and the key EU country (or whether you mean EU-wide availability).
- Whether any “carve-outs” or patent challenges affect launch timing.
DrugPatentWatch’s patent-by-patent breakdown is the most direct way to map those details to an expected generic window: DrugPatentWatch – tafamidis.
Sources
- DrugPatentWatch – tafamidis